Journal of Disability and Oral Health
- Cover Date:
- December 2006
- Print ISSN:
- 1470-8558
- Electronic ISSN:
- 1754-2758
- Vol:
- 7
- Issue:
- 3
Salivary methotrexate following IV therapy for osteosarcoma: a pilot study
Aim: Exposure to antineoplastic drugs poses risk to health providers who may be treating children u n d e r g o i n g cancer or immune therapy. Objective: This study compares methotrexate (MTX) concentrations in saliva and plasma against a concentration standard for lymphocyte mutagenicity (0.100 µmol/L). Design: Five osteosarcoma patients expectorated 5mL of unstimulated saliva into a sterile collection tube at 24, 48 and 72 hours post-MTX administration, paralleling blood sampling, and yielding 33 samples. Saliva was analysed using fluorescence polarization immunoassay (FPIA) to determine MTX concentrations; creatinine and blood urea nitrogen (BUN) also were measured using standard techniques. Results: Mean saliva MTX at 24 hours (0.138µmol/L) exceeded in vitro mutagenic standard, but did not at 48h and 72h post infusion. Key Words: Methotrexate, anti-neoplastic drugs, dental personnel, saliva, plasma
- Article Price
- £15.00
- Institution Article Price
- £15.00
- Page Start
- 153
- Page End
- 155
- Authors
- F Michael Beck, Reginald Eswuedo, Dennis J McTigue, Paul S Casamassimo, Sarat Thikkurissy
Articles from this issue
- Title
- Pg. Start
- Pg. End
- Defining the population requiring special care dentistry using the International Classification of Functioning, Disability and Health – a personal view
- 143
- 152
- Oral disease experience of adults with severe disability, prior to receiving dental treatment under general anaesthesia
- 173
- 175